Literature DB >> 21619907

Bis-(3',5')-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant.

Thomas Ebensen1, Rimma Libanova, Kai Schulze, Tetyana Yevsa, Michael Morr, Carlos A Guzmán.   

Abstract

New effective adjuvants are required to improve the performance of subunit vaccines. Here, we showed that bis-(3',5')-cyclic dimeric adenosine monophosphate (c-di-AMP), a second messenger molecule in bacteria and archaea, exerts strong adjuvant activities when delivered by mucosal route. In vitro studies showed that c-di-AMP was able to both stimulate pre-activated murine macrophages and promote the activation and maturation of dendritic cells of murine and human origin. Co-administration of c-di-AMP with β-galactosidase (β-Gal) by intranasal route to BALB/c mice resulted in the elicitation of significantly higher serum antigen-specific IgG titres than in controls. The induction of local immune responses was shown by the production of antigen-specific secretory IgA in different mucosal territories. In addition, strong cellular immune responses were observed against both the β-Gal protein and a peptide encompassing its MHC class I-restricted epitope. The ratio of β-Gal-specific antibodies and the secreted cytokine profiles by in vitro re-stimulated splenocytes suggested that a balanced Th1/Th2/Th17 response pattern is promoted by c-di-AMP. When C57BL/6 mice were immunized with OVA and c-di-AMP, vigorous in vivo CTL responses were also observed. These results indicated that c-di-AMP exhibits a high potential as adjuvant for the development of mucosal vaccines, in particular when cellular immunity is needed.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21619907     DOI: 10.1016/j.vaccine.2011.05.026

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  51 in total

Review 1.  Modulating immunity as a therapy for bacterial infections.

Authors:  Robert E W Hancock; Anastasia Nijnik; Dana J Philpott
Journal:  Nat Rev Microbiol       Date:  2012-03-16       Impact factor: 60.633

Review 2.  Cyclic dinucleotides and the innate immune response.

Authors:  Olga Danilchanka; John J Mekalanos
Journal:  Cell       Date:  2013-08-29       Impact factor: 41.582

Review 3.  Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems.

Authors:  Prosper N Boyaka
Journal:  J Immunol       Date:  2017-07-01       Impact factor: 5.422

4.  STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade.

Authors:  Juan Fu; David B Kanne; Meredith Leong; Laura Hix Glickman; Sarah M McWhirter; Edward Lemmens; Ken Mechette; Justin J Leong; Peter Lauer; Weiqun Liu; Kelsey E Sivick; Qi Zeng; Kevin C Soares; Lei Zheng; Daniel A Portnoy; Joshua J Woodward; Drew M Pardoll; Thomas W Dubensky; Young Kim
Journal:  Sci Transl Med       Date:  2015-04-15       Impact factor: 17.956

Review 5.  A decade of research on the second messenger c-di-AMP.

Authors:  Wen Yin; Xia Cai; Hongdan Ma; Li Zhu; Yuling Zhang; Shan-Ho Chou; Michael Y Galperin; Jin He
Journal:  FEMS Microbiol Rev       Date:  2020-11-24       Impact factor: 16.408

6.  Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants.

Authors:  Melissa C Hanson; Monica P Crespo; Wuhbet Abraham; Kelly D Moynihan; Gregory L Szeto; Stephanie H Chen; Mariane B Melo; Stefanie Mueller; Darrell J Irvine
Journal:  J Clin Invest       Date:  2015-05-04       Impact factor: 14.808

Review 7.  Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants.

Authors:  Thomas W Dubensky; David B Kanne; Meredith L Leong
Journal:  Ther Adv Vaccines       Date:  2013-11

8.  Sublingual targeting of STING with 3'3'-cGAMP promotes systemic and mucosal immunity against anthrax toxins.

Authors:  Tara L Martin; Junbae Jee; Eunsoo Kim; Haley E Steiner; Estelle Cormet-Boyaka; Prosper N Boyaka
Journal:  Vaccine       Date:  2017-03-24       Impact factor: 3.641

9.  A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination.

Authors:  Robert D Junkins; Matthew D Gallovic; Brandon M Johnson; Michael A Collier; Rebekah Watkins-Schulz; Ning Cheng; Clément N David; Charles E McGee; Gregory D Sempowski; Ivo Shterev; Karen McKinnon; Eric M Bachelder; Kristy M Ainslie; Jenny P-Y Ting
Journal:  J Control Release       Date:  2017-11-21       Impact factor: 9.776

10.  B Cell-Intrinsic STING Signaling Triggers Cell Activation, Synergizes with B Cell Receptor Signals, and Promotes Antibody Responses.

Authors:  Melissa M Walker; Bergren W Crute; John C Cambier; Andrew Getahun
Journal:  J Immunol       Date:  2018-10-03       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.